Could a cheap rectal pill cut C-Section bleeding?
NCT ID NCT07188207
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether giving a rectal dose of misoprostol before a planned C-section, on top of the usual oxytocin, can reduce blood loss during and after surgery. About 282 women having elective C-sections will be randomly assigned to receive either standard care or standard care plus misoprostol. The goal is to find a simple, low-cost way to prevent dangerous bleeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
misoprostol (rectal) plus oxytocin (intravenous)
What this could lead to
If it works, this could offer a cheap, heat-stable way to lower the risk of dangerous bleeding during planned C-sections.
What could go wrong
This is a small, early-stage trial (282 participants) and the added benefit over standard care may be small. Misoprostol can cause side effects like shivering or fever.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTPARTUM HEMORRHAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••